# SKYSCRAPER-03 (NCT04513925)

> A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04513925
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-small Cell Lung Cancer (NSCLC)
- Interventions: Atezolizumab; Tiragolumab; Durvalumab
- Enrollment: 829
- Primary outcome: Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)
- Primary outcome: PFS, as Assessed by an IRF in FAS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 17
- Podcasts: 2
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=skyscraper-03-nct04513925

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04513925", "email": "<work email>"}; the inbox owner confirms by the emailed link.